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Edited by Horst FeldmannAbstract The mitochondrial myopathy, encephalopathy, lactic
acidosis and stroke-like episodes syndrome (MELAS) is a rare
congenital disorder of mitochondrial DNA. Five single nucleotide
substitutions within the human mitochondrial tRNALeu(UUR)
gene have been reported to be associated with MELAS. Here,
we provide in vitro evidence that the aminoacylation capacities
of these ﬁve hmtRNALeu(UUR) transcripts are reduced to diﬀer-
ent extents relative to the wild-type hmtRNALeu(UUR) tran-
script. A thermal denaturation experiment showed that the
A3243G and T3291C mutants, which were the least charged
by LeuRS, have fragile structures. In addition, the T3291C mu-
tant can inhibit aminoacylation of the wild-type hmtRNA-
Leu(UUR), indicating that it may act as an inhibitor in the
mitochondrial heteroplasmic environment.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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The aminoacylation of tRNAs with cognate amino acids by
aminoacyl-tRNA synthetases (aaRS) is a key step in the
decoding of genetic information [1]. The eﬃciency and ﬁdelity
of protein synthesis are dependent on the presence of func-
tional tRNAs.
In the last two decades, an increasing number of single
nucleotide substitutions within the human mitochondrial
tRNA (hmtRNA) genes have been linked to a variety of mul-
tisystem disorders [2]. More than 90 mutations have been re-
ported in 21 hmtRNA genes [3]. The human mitochondrial
tRNALeu(UUR) [hmtRNALeu(UUR)] gene (human mitochon-
drial genome 3231–3305) is a hotspot for pathology-related
mutations. Over 20 mutations have been found within thisAbbreviations: MELAS, mitochondrial myopathy, encephalopathy, l-
actic acidosis, and stroke-like episodes syndrome; hmLeuRS, human
mitochondrial leucyl-tRNA synthetase; hmtRNA, human mitochon-
drial tRNA; hmDNA, human mitochondrial DNA; E. coli, Escherichia
coli
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doi:10.1016/j.febslet.2004.11.004region (see http://www.mitomap.org). Investigation of their de-
tailed molecular inﬂuences will help to elucidate their pathoge-
netic mechanism and will provide information on the
mechanisms of mitochondrial protein synthesis.
The mitochondrial myopathy, encephalopathy, lactic acido-
sis and stroke-like episodes syndrome (MELAS) is a rare con-
genital disorder of human mitochondrial DNA (hmDNA) [4].
It is reported to be associated with ﬁve single nucleotide substi-
tutions (A3243G, A3252G, C3256T, T3271C, and T3291C) [5–
9] within the hmtRNALeu(UUR) gene (Fig. 1). Mutation at
A3243 of hmtRNALeu(UUR) is reported to decrease the eﬃ-
ciency of aminoacylation in vivo and in vitro [10–12]. The
T3271C variant also shows attenuated aminoacylation in vitro
despite to less degree [12]. The eﬀects of the substitutions at
other three positions, A3252G, C3256T, and T3291C, have
not yet been reported.
We investigated the processing of human mitochondrial leu-
cyl-tRNA synthetase (hmLeuRS) in insect cell and found that
the precursor protein is cleaved between residues 39 and 40
[13]. The gene encoding the mature hmLeuRS was constructed
in a plasmid and was overexpressed in Escherichia coli (E. coli )
[14]. The protein, which we designated hmLeuRS-40, was puri-
ﬁed from the E. coli transformant by one step Ni–NTA aﬃnity
chromatography. The puriﬁed protein had a speciﬁc activity of
125 unit/mg (kcat = 2.1 · 101 s1) when E. coli tRNALeu was
used as the substrate. This high speciﬁc activity allows the
puriﬁed protein to be used for analyzing the aminoacylation
of hmtRNALeu mutants, information that will help to clarify
the pathogenic mechanisms of hmtRNALeu mutation-associ-
ated diseases.
In the present study, we constructed the other three
MELAS-associated point mutations (A3252G, C3256T, and
T3291C) in hmtRNALeu(UUR). Comparison of the aminoacy-
lation capacities of the ﬁve MELAS-associated variants in vi-
tro showed that their aminoacylation levels are reduced
compared to wild-type hmtRNALeu(UUR), but to varying ex-
tents. Thermal denaturation experiments showed that the se-
verely attenuated charging of A3243G and T3291C mutant
tRNAs corresponds with signiﬁcantly decreased melting tem-
peratures (Tm), indicating that they have more fragile struc-
tures than the wild-type tRNA. Furthermore, the T3291C
variant competitively inhibited aminoacylation of the wild-
type hmtRNALeu(UUR), indicating that the mutant may inhi-
bit charging of the substrate in the potentially heteroplasmic
environment of the mitochondria with mixtures of wild-type
and mutant tRNAs [15,16].ation of European Biochemical Societies.
Fig. 1. Location of MELAS-associated mutations within the clover-
leaf secondary structure of human mitochondrial tRNALeu(UUR).
The mutations are indicated with arrows. The numbers corresponding
to the genomic locations are shown in italics and the corresponding
secondary structure locations are presented in brackets.
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2.1. Materials
Except where noted, all chemicals were purchased from Sigma (St.
Louis, MO, USA). [14C]Leucine was purchased from Amersham Bio-
science (Buckinghamshire, UK). Kinase, ligase, restriction endonuc-
leases, and RNasin ribonuclease inhibitor were obtained from
Promega (Madison, WI, USA). T7 RNA polymerase and the hm-
LeuRS-40 protein were puriﬁed from overexpressing E. coli [14,17].
2.2. Preparation of hmtRNAsLeu(UUR) by in vitro transcription
Plasmids encoding the tRNA transcripts were constructed by
ligating overlapping oligonucleotides into a pUC19 plasmid between
the EcoRI and BamHI cleavage sites. The tRNA constructs were
placed between a T7 RNA polymerase promoter sequence and a
BstOI cleavage site and were connected to the 3 0 end of a hammer-
head ribozyme sequence to increase the transcription yields [18]. The
clones for the wild-type hmtRNALeu(UUR) and ﬁve variants,
A3243G, A3252G, C3256T, T3271C, and T3291C (numbering
according to their location in the hmDNA), were obtained. The
identities of the clones were conﬁrmed by DNA sequencing.
In vitro transcription and subsequent ribozyme cleavage were per-
formed as described by Sohm et al. [12] and Fechter et al. [18], respec-
tively. The transcripts were puriﬁed to single nucleotide resolution on
polyacrylamide-urea gels (15%), excised, and extracted for 4 h at 25 C
with a solution of 125 mM NH4Ac, 0.5 lM EDTA, and 0.025% SDS.
After ethanol precipitation from this extract, the transcripts were re-
solved in diethyl pyrocarbonate-treated deionized distilled water con-
taining 12 mM MgCl2. All hmtRNA
Leu(UUR) transcripts were
annealed by heating for 3 min at 80 C and cooled on ice for 30
min. As the denaturation–renaturation process may aﬀect the folding
of transcript, we attempted to optimize the folding condition for each
tRNA variant. However, no obvious increase in charging level was de-
tected for each transcript. The tRNA concentrations were determined
by UV absorbance at 260 nm. Extinction coeﬃcients were calculated
from the sequence of each tRNA [19].
2.3. Assay of tRNA charging capacity
The time course of aminoacylation was assessed at 37 C in a 70 ll
reaction mixture containing 50 mM HEPES, pH 7.6, 25 mM KCl, 10
mM MgCl2, 2.5 mM ATP, 1 mM spermidine, 0.5 U/ll ribonucleaseinhibitor, 100 lg/ml bovine serum albumin, 20 lM [14C]leucine (402
cpm/pmol), and 1.5 lM hmtRNALeu(UUR) transcript. The reactions
were initiated by the addition of 1 lM hmLeuRS-40. At various time
points, a 10 ll aliquot was removed and spotted onto Whatman
3MM ﬁlter paper, precipitated with 5% trichloroacetic acid, and
washed with 5% trichloroacetic acid and ethanol. Adsorbed radioac-
tivity on the ﬁlter papers was measured by scintillation counting. The
maximum proportion of transcript that could be aminoacylated (pla-
teau) was determined in 40-min incubation times.
The aminoacylation kinetic constants of hmLeuRS-40 for tRNA-
Leu(UUR) and its mutants were measured at 37 C as described above,
except that the concentration ranges of tRNAs and hmLeuRS-40 were
adjusted according to the accepting activities of tRNA (1–20 lM for
tRNAs and 0.3–1 lM for hmLeuRS-40). The apparent kinetic param-
eters, kcat and Km, of hmLeuRS-40 for hmtRNA
Leu(UUR) and its mu-
tants were derived from Eadie-Hofstee plots and were the average of
three independent determinations.2.4. Assay the eﬀect of mutant tRNA to wild-type tRNALeu(UUR)
aminoacylation
The eﬀect of the A3243G or T3291C mutants on wild-type
hmtRNALeu(UUR) aminoacylation was determined by addition of
either tRNA variant to a wild-type hmtRNALeu(UUR) aminoacyla-
tion mixture. The pH and buﬀer were the same as in the aminoacy-
lation assay, but 1.5 lM wild-type hmtRNALeu(UUR) and 0.3 lM
hmLeuRS-40 were used. Diﬀerent concentrations (0, 1.5, 3, or 4.5
lM) of the A3243G or T3291C variant were added prior to initiating
the reaction. The reactions were carried out at 37 C for 5 min and
15 ll aliquots were removed for monitoring the generation of Leu-
tRNAs.
The pattern of inhibition of wild-type tRNALeu(UUR) aminoacyla-
tion by the T3291C variant was determined from Lineweaver–Burk
plots. In these experiments, the concentrations of wild-type tRNA-
Leu(UUR) were 1, 1.25, 2, and 5 lM, and the concentrations of the
T3291C variant were 0, 2, and 5 lM. Except for the use of 0.3 lM
hmLeuRS-40, the other reaction conditions were the same as described
for the standard aminoacylation assay.
2.5. Determination of the Tm of hmtRNA
Leu(UUR) mutants
The tRNA variants (0.5 lM) were prepared in 50 mMHEPES buﬀer,
pH 7.6, containing 25 mM KCl and 10 mM MgCl2. All tRNAs were
annealed before the thermal denaturation experiment. Denaturation
of the samples was achieved by increasing the temperature from 35 to
89 C and was followed at 260 nm. The Tm value was determined as
the maximum of the ﬁrst derivative of the melting curves measured at
260 nm.3. Results
3.1. Construction of hmtRNALeu(UUR) mutants
The aminoacylation activity for a set of hmtRNAsLeu(UUR)
mutants, including A3243G, A3243T, and T3271C, has been
investigated to elucidate the role of hmtRNALeu(UUR) in
some pathological disorders [12]. In the present work, we con-
structed and studied the activities of ﬁve MELAS-related mu-
tant hmtRNALeu(UUR) transcripts. These mutations are
located at diﬀerent regions of the tRNA cloverleaf secondary
structure (Fig. 1). Mutations A3243G and A3252G are in
the D-loop of the tRNA at positions 14 and 21, respectively;
mutation C3256T replaces a GC base pair with a GU mispair
at position 25 in the canonical D-stem sequence; mutation
T3271C gives rise to an AC mismatch at position 40 in the
anticodon stem of hmtRNALeu(UUR); and the T3291C substi-
tution changes the U residue at position 60 in the theoretical
TWC loop to a C. Although the locations of these mutations
are known, the eﬀects of A3252G, C3256T, and T3291C on
the leucylation of hmtRNALeu(UUR) have not been previ-
ously reported.
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the eﬃciency of leucylation
We next examined the eﬀects of the ﬁve MELAS-associated
mutations on the ability of hmtRNALeu(UUR) to be leucy-
lated by hmLeuRS-40. As shown in Fig. 2, all of the mutants
had decreased abilities to be aminoacylated compared to the
wild-type hmtRNALeu(UUR). Under the experimental condi-
tions, the plateau value of the wild-type tRNALeu(UUR)
aminoacylated by hmLeuRS-40 is 70%. However, for the
C3256T, A3252G, and T3291C variants only 24%, 17%, and
less than 4%, respectively, can be aminoacylated. Similar to
the ﬁndings of Sohm et. al. [12], the A3243G and T3271C vari-
ants were 7% and 30% charged, respectively. Thus, all
MELAS-associated point mutations decreased the eﬃciency
of leucylation and the accepting activity of T3291C was the
lowest among the ﬁve mutants.
The aminoacylation assay of hmtRNALeu(UUR) showed
that these single nucleotide substitutions mainly decrease the
catalytic rate of hmLeuRS instead of the apparent binding
aﬃnity (Table 1). In fact, Km values of hmLeuRS-40 for all
hmtRNALeu(UUR) mutants were lower than that for the
wild-type hmtRNALeu(UUR), indicating stronger binding of
all hmtRNALeu(UUR) mutants to hmLeuRS-40. The Km value
for T3291C was the smallest (4.5-fold reduction), and those for
T3271C and C3256T were similar to the wild-type. Although
the change in Km of hmLeuRS-40 for hmtRNA
Leu(UUR) mu-
tants was not signiﬁcant, the kcat values of hmLeuRS-40 for
hmtRNALeu(UUR) mutants clearly decreased. Compared to
the wild-type hmtRNALeu(UUR), the kcat value for T3291C
decreased 345-fold; even for the T3271C variant there wasFig. 2. Eﬀects of MELAS-related mutations on the aminoacylation of
human mitochondrial tRNALeu(UUR). Assays contained 1.5 lM
tRNA transcript and 1 lM hmLeuRS-40 and were performed at 37 C.
Charging levels are expressed as percentages of charged tRNA vs. the
total amount of speciﬁc tRNA.
Table 1
Apparent kinetic parameters of in vitro aminoacylation of wild-type and M
HmtRNALeu(UUR) transcripts kcat (10
3 s1) Km (lM)






Aminoacylation reactions were as described in Section 2. The L values in th
independent determinations.an approximately 4-fold reduction in the kcat. For these
hmtRNALeu(UUR) mutants, the aminoacylation eﬃciency
(kcat/Km) of hmLeuRS-40 decreased 3.7- to 74.5-fold as com-
pared to that for the wild-type. Speciﬁcally, the decrease in eﬃ-
ciency was the largest for the T3291C mutant (74.5-fold); for
the T3271C, A3252G, and C3256T variants, the eﬃciency
was reduced by approximately 4-fold; and for A3243G, the
eﬃciency was reduced 12.3-fold.
3.3. Determination of Tm for hmtRNA
Leu(UUR) mutants
We suspected that the eﬀect of single substitutions on the
aminoacylation of hmtRNALeu(UUR) is due to altered fold-
ing. This possibility was investigated by comparing the Tm of
the mutants (Table 2). In a thermal denaturation experiment,
the Tm value of the wild-type tRNA
Leu(UUR) transcript was
74.5 C. There were obvious decreases in the Tm of the
A3243G (65.5 C) and T3291C (67 C) variants. In contrast,
the Tm values of A3252G, C3256T, and T3271C variants were
very similar to that of wild-type tRNA.
3.4. T3291C mutant transcript inhibits the leucylation of
wild-type hmtRNALeu(UUR)
Kinetic assays show that the T3291C mutation severely de-
creases aminoacylation eﬃciency of hmtRNALeu(UUR). A
further experiment was carried out to monitor aminoacylation
in heterogeneous mixtures of wild-type hmtRNALeu(UUR)
and the T3291C variant. As shown in Fig. 3A, the charging
of wild-type hmtRNALeu(UUR) was decreased by the addition
of the T3291C mutant. This result is consistent with the idea
that the T3291C variant binds hmLeuRS, but cannot be eﬃ-
ciently charged. We performed the same experiment with a
mixture of wild-type hmtRNALeu(UUR) and the A3243G var-
iant, but did not observe inhibition.
Inhibition of the wild-type tRNA aminoacylation by the
T3291C variant was analyzed by Lineweaver–Burk double re-
ciprocal plots. As revealed in Fig. 3B, as the concentration of
T3291C was lowered, the Km increased, but there was no sig-
niﬁcant decrease in Vmax. This shows that the T3291C variant
is a competitive inhibitor of the aminoacylation of wild-type
tRNALeu(UUR). In other words, the T3291C variant com-
petes with wild-type tRNA at least at some putative tRNA
binding sites on hmLeuRS.4. Discussion
There is a great deal of interest and excitement recently in
understanding the pathological mechanisms of mitochondrial
diseases. A given mutation in a tRNA gene may have impactsELAS-related mutant hmtRNALeu(UUR) transcripts by hmLeuRS
kcat/Km (10







is table were the average values with a variation of <15% from three
Table 2
The melting temperature of hmtRNALeu(UUR) transcripts
HmtRNALeu(UUR) transcripts Melting temperature
wild type 74.5 ± 1.5
A3243G 65.5 ± 0.5
A3252G 74.0 ± 0.5
C3256T 75.5 ± 1.5
T2371C 75.5 ± 1.5
T3291C 67.0 ± 1.0
The melting temperature was measured as described in Section 2. All
data presented here were the average values from two independent
determinations.
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ing of the termini, aminoacylation, and, thus, ultimately in-
duce diseases [10,11,20,21]. In vitro transcription is an
eﬃcient approach to systematically study the eﬀects of diﬀerent
hmtRNA mutations. Although the tRNAs produced through
in vitro transcription are devoid of base modiﬁcation and
sometimes do not achieve the classical cloverleaf structure
[22,23], they have been successfully used in studying the eﬀects
of pathology-related mutations in the genes of hmtRNAIle
[24,25], hmtRNALys [26] or hmtRNALeu [12,27]. Our work is
attempted to reveal the mechanism of MELAS based on the
related tRNA aminoacylation.Fig. 3. Mutant T3291C is an inhibitor of wild-type hmtRNA-
Leu(UUR). (A) Eﬀect of the A3243G or T3291C variant on wild-type
hmtRNALeu(UUR) aminoacylation. Diﬀerent concentrations of the
A3243G or T3291C variants were mixed with 1.5 ll wild-type tRNA,
and the reaction was carried out with 0.3 lM hmLeuRS-40 for 5 min at
37 C. (B) Lineweaver–Burk plot of the kinetic data for the T3291C
variant. The reciprocal of reaction velocity is plotted vs. the reciprocal
of the wild-type tRNALeu(UUR) concentration at 0 (j), 2 (.), and 5
(d) lM T3291C.To gain insight into the pathogenic mechanisms of the
MELAS-associated substitutions in hmtRNALeu(UUR), we
constructed ﬁve MELAS-associated tRNA variants and char-
acterized their aminoacylation in vitro. We found that the
accepting activity of the tRNA was decreased by each muta-
tion, although to diﬀerent extent. The impaired aminoacyla-
tion was consistent with the defect in mitochondrial protein
synthesis found in trans-mitochondrial yeast [28]. The substi-
tutions of 3291T to C and 3243A to G dramatically
decreased the ability of tRNA to be aminoacylated. Subse-
quent measurements of Tm indicated that the structures of
A3243G and T3291C mutants were far more fragile than
those of other tRNA variants. Therefore, the aminoacylation
deﬁciency appears to be associated with instability in the
tRNA structure. The A3243G mutation corresponds to an
A14G substitution in the D-loop of the tRNA. It eliminates
a reverse Hoogsteen pairing between A14 and U8 and is
thought to impair the tertiary structure of tRNA [29]. The
T3291C mutation corresponds to a U60C substitution in
the TWC loop. Nucleotide 60, which is not involved in the
canonical tRNA tertiary interactions, has not been found
as an aminoacylation identity element in prokaryotic or
eukaryotic tRNALeu investigated so far [22]. Thus, U60 might
contribute to the hmtRNALeu(UUR) structure and identity in
an indirect way.
We also found that the T3291C variant can competitively
inhibit the aminoacylation of the wild-type hmtRNA-
Leu(UUR). Although this variant is the least leucylated by
hmLeuRS, it appears to retain some structural elements nec-
essary for binding to hmLeuRS. The data herein suggested
that, besides the low accepting activity, the T3291C variant
might disturb the aminoacylation of the wild-type tRNA
in the potentially heteroplasmic environment of the mito-
chondria. This result provided an explanation for the posi-
tive correlation between the relative amount of T3291C
mutation and the severity of the pathological phenotype
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